KCM
SRPT icon

Kingdon Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Kingdon Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-100,000
Closed -$3.21M – 140
2015
Q3 		$3.21M Buy
+100,000
New +$3.39M 0.15% 99

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Kingdon Capital Management's SRPT Position: Q4 2017 in Review

Kingdon Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2017, closing a stake of 10,000 shares — an estimated $454K sold.

Kingdon Capital Management first reported a position in SRPT in Q3 2017 and held it in 1 quarter. The position peaked at $454K in Q3 2017. 254 funds tracked by Wall St. Rank hold SRPT as of Q4 2017.

  • Kingdon Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Kingdon Capital Management sold 10,000 Sarepta Therapeutics shares in Q4 2017, an estimated $454K.
  • Kingdon Capital Management first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 1 quarter.
  • Kingdon Capital Management's Sarepta Therapeutics position peaked at $454K in Q3 2017.
  • 254 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2017.

Based on Kingdon Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.